Patients’ characteristics (validation cohort)
| Variable . | Validation cohort (N = 64 patients) . |
|---|---|
| COO (NanoString) | |
| ABC | N/A |
| GCB | N/A |
| UNC | N/A |
| MYC/BCL-2 DEXP mRNA | |
| Yes | N/A |
| No | N/A |
| IPI, n (%) | |
| Low (0-2) | 45 (70) |
| High (3-5) | 19 (30) |
| Sex, n (%) | |
| Female | 29 (45) |
| Male | 35 (55) |
| Age, y, median (range) | 61.6 (18.1-83.4) |
| Stage, n (%) | |
| I | 6 (9) |
| II | 20 (31) |
| III | 3 (5) |
| IV | 35 (55) |
| Follow-up, mo, median (range) | 50.26 (0.89-135.48) |
| Variable . | Validation cohort (N = 64 patients) . |
|---|---|
| COO (NanoString) | |
| ABC | N/A |
| GCB | N/A |
| UNC | N/A |
| MYC/BCL-2 DEXP mRNA | |
| Yes | N/A |
| No | N/A |
| IPI, n (%) | |
| Low (0-2) | 45 (70) |
| High (3-5) | 19 (30) |
| Sex, n (%) | |
| Female | 29 (45) |
| Male | 35 (55) |
| Age, y, median (range) | 61.6 (18.1-83.4) |
| Stage, n (%) | |
| I | 6 (9) |
| II | 20 (31) |
| III | 3 (5) |
| IV | 35 (55) |
| Follow-up, mo, median (range) | 50.26 (0.89-135.48) |
N/A, not applicable.